Oncology Market Accelerates: 3 Stocks to Watch in Cancer Innovation

The global oncology market is rapidly evolving due to rising cancer incidence, an aging population, and continued scientific innovation. In 2026, the United States is projected to record nearly 2.1 million new cancer cases and more than 626,000 cancer-related deaths. Advances in immunotherapy, targeted medicines, and personalized cancer vaccines have expanded treatment options beyond conventional chemotherapy and radiation.

Emerging technologies such as genomic sequencing, artificial intelligence, and machine learning are speeding biomarker discovery, refining patient selection, and enabling earlier diagnosis. Pharmaceutical companies like Novartis (NVS), AstraZeneca (AZN), J&J (JNJ), Pfizer (PFE), AbbVie, Merck, Bristol Myers Squibb, and Eli Lilly continue to prioritize oncology through increased investment and pipeline expansion.

Autolus Therapeutics (AUTL) is a commercial-stage company developing next-generation T cell therapies targeting cancer and autoimmune diseases. Its marketed therapy, Aucatzyl, has seen a strong launch in the United States and the UK, with 2026 net product revenues guided at $120-$135 million.

NextCure (NXTC) is a clinical-stage biotech focused on developing targeted therapies to treat cancer. Its lead asset, SIM0505, is being evaluated in a phase I study across multiple advanced solid tumors, with early dose-escalation data showing encouraging antitumor activity in heavily pretreated gynecologic cancer patients.

Recursion Pharmaceuticals (RXRX) is a clinical-stage TechBio company decodes biology and chemistry to industrialize drug discovery. Its most advanced oncology asset, REC-1245, is being evaluated in the phase I/II DAHLIA study for the treatment of biomarker-enriched solid tumors and lymphoma.